Document is current

Empagliflozin und kardiovaskuläre Endpunkte bei Patienten mit Diabetes mellitus Typ 2

Crossref DOI link: https://doi.org/10.1007/s11560-016-0049-2

Published Online: 2016-03-30

Published Print: 2016-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy